Karen-Sue B. Carlson, MD, PhD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Moorland Reserve Health Center

Specialties

Medical Oncology
Hematology

Languages

English

Cancer Center - Froedtert Hospital

(414) 805-0505

Moorland Reserve Health Center

(262) 798-7200

Education

MD - Doctor of Medicine
PhD

Biography

Karen-Sue Barker Carlson, MD, PhD, is Assistant Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in acute and chronic myeloid leukemia, adolescent and young adult leukemia, myelodysplastic syndromes and myeloproliferative disorders. She received her MD and PhD in 2004 from the University of Wisconsin – Madison. In 2006, she completed her postdoctoral fellowship at The Rockefeller University in New York. She was awarded the F.M. Kirby Postdoctoral Fellowship in Sensory Neuroscience during her fellowship. Dr. Carlson completed her residency in internal medicine and subsequent Fellowship in Hematology and Medical Oncology at Weill Cornell Medical Center, New York Presbyterian Hospital, New York. In her final year, Dr. Carlson served as Chief Hematology and Oncology Fellow. Dr. Carlson held the position of Assistant Professor, Department of Medicine, Division of Hematology and Oncology at Weill Cornell Medical Center prior to joining MCW.

Research Interests

Dr. Carlson's basic and clinical research focus on the bone marrow microenvironment and its impact on normal and leukemic blood cell production. Dr. Carlson is board certified in Internal Medicine and Hematology.

Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?

(Carlson KS, Cunningham A, Stahl M, Winer E, Michaelis LC.) Acta Haematol. 2024;147(2):122-132 PMID: 38071966 12/11/2023
MiR-9-1 controls osteoblastic regulation of lymphopoiesis.

(Zhang Y, Lin D, Zheng Y, Chen Y, Yu M, Cui D, Huang M, Su X, Sun Y, Chen Y, Qian Z, Carlson KS, Wen R, Wang D.) Leukemia. 2023 Nov;37(11):2261-2275 PMID: 37670087 PMCID: PMC10844005 SCOPUS ID: 2-s2.0-85169811460 09/06/2023
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy.

(Kleman A, Singavi A, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns R, Steinhardt GF, Rao S, Carlson K.) Blood Adv. 2023 Sep 26;7(18):5549-5553 PMID: 36724511 PMCID: PMC10514068 SCOPUS ID: 2-s2.0-85164933174 02/02/2023
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study.

(Zhang T, Auer P, Dong J, Cutler C, Dezern AE, Gadalla SM, Deeg HJ, Nazha A, Carlson KS, Spellman S, Bolon YT, Saber W.) J Hematol Oncol. 2023 Apr 11;16(1):37 PMID: 37041565 PMCID: PMC10088148 SCOPUS ID: 2-s2.0-85152260295 04/12/2023
Pediatric Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical Presentations, Significance, and Biology.

(Zorn KE, Cunningham AM, Meyer AE, Carlson KS, Rao S.) Cancers (Basel). 2023 Feb 24;15(5) PMID: 36900239 PMCID: PMC10000481 03/12/2023
The extracellular matrix controls stem cell specification and crypt morphology in the developing and adult mouse gut.

(Ramadan R, Wouters VM, van Neerven SM, de Groot NE, Garcia TM, Muncan V, Franklin OD, Battle M, Carlson KS, Leach J, Sansom OJ, Boulard O, Chamaillard M, Vermeulen L, Medema JP, Huels DJ.) Biol Open. 2022 Dec 15;11(12) PMID: 36350252 PMCID: PMC9713296 SCOPUS ID: 2-s2.0-85142918558 11/10/2022
Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.

(Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, Atallah E.) Leuk Res. 2022 Dec;123:106984 PMID: 36401944 SCOPUS ID: 2-s2.0-85141943453 11/20/2022
Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.

(Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM.) Yale J Biol Med. 2022 Mar;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022
Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.

(Khan M, Roddy JT, Hernandez JR, Bursch K, Bal N, Carlson KS, Bergl PA.) Br J Haematol. 2021 Sep;194(6):1083-1085 PMID: 34101165 06/09/2021
Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.

(Wang W, Auer P, Zhang T, Spellman S, Carlson KS, Nazha A, Bolon YT, Saber W.) Transplant Cell Ther. 2021 Aug;27(8):659.e1-659.e6 PMID: 33992829 PMCID: PMC8421055 SCOPUS ID: 2-s2.0-85108524869 05/17/2021
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.

(Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS.) Leuk Lymphoma. 2021 Jan;62(1):158-166 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020
Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant.

(Dhakal B, Wang T, Kuxhausen M, Zhu F, Taylor C, Spellman SR, Verneris MR, Hsu K, Fleischhauer K, Lee SJ, Bolon YT, Carlson KS, Nazha A, Saber W.) Leuk Lymphoma. 2021 Jan;62(1):229-233 PMID: 32924688 PMCID: PMC7939047 SCOPUS ID: 2-s2.0-85090933926 09/15/2020